Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGS 62P1

Next Previous
X
Search
Drug Profile

AGS 62P1

Alternative Names: AGS-62P1; ASP-1235

Latest Information Update: 13 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambrx
  • Developer Astellas Pharma
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Fms-like tyrosine kinase 3 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
  • 25 Mar 2021 Agensys terminates phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA and Canada (IV) in September 2020 due to lack of efficacy (NCT02864290)
  • 09 Dec 2020 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA, Canada (IV) (Astellas Pharma pipeline, December 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top